[Clinical trial of N-cyclohexyl-N-methyl(-2-amino-3,5-dibromobenzyl)-ammonium chloride associated with antibiotics in therapy of chronic bronchopneumopathies].
D000328:Adult; D000368:Aged; D000814:Aniline Compounds / Q000627:therapeutic use*; D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use; D001593:Benzyl Compounds / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D003514:Cyclohexylamines / Q000627:therapeutic use; D004357:Drug Synergism; D005100:Expectorants / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011656:Pulmonary Emphysema / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D012830:Silicotuberculosis / Q000188:drug therapy; D013752:Tetracycline / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D000814:Aniline Compounds; D000995:Antitubercular Agents; D001593:Benzyl Compounds; D003514:Cyclohexylamines; D005100:Expectorants; D013752:Tetracycline
Sperimentazione clinica dell'N-cicloesil-N-metil-(i-amino-3,5-dibromobenzil)-ammonio cloruro associato ad antibiotici nella terapia delle broncopneumopatie croniche.